Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Works matching IS 13570560 AND DT 2018 AND VI 35 AND IP 2
Results: 3
1
2
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
- Published in:
- 2018
- By:
- Publication type:
- journal article
3
Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
- Published in:
- 2018
- By:
- Publication type:
- journal article